Biofrontera INC 10-Q quarterly reports

Biofrontera Inc. reported a 32.9% increase in product revenue for Q2 2026, driven by higher Ameluz sales, but continues to face substantial doubt regarding its going concern status and significant operational challenges from regulatory actions.

Biofrontera Inc. announced its first quarter 2026 financial results, reporting a 17.4% increase in net product revenue to $10.1 million, driven by higher Ameluz sales.

Biofrontera Inc. reported a narrowed nine-month net loss, completed a strategic acquisition of Ameluz rights, and sold its Xepi product line, while addressing Nasdaq compliance issues.

Biofrontera Inc. reported increased product revenue but a widened Q2 net loss, alongside critical Nasdaq compliance issues and a going concern warning, while securing US rights to its core products and raising $8.5M in new capital.

Biofrontera Inc. saw a revenue increase in Q1 2025 but faces substantial doubt about its ability to continue as a going concern due to liquidity issues and Nasdaq compliance concerns.

Biofrontera Inc. announced its third quarter 2024 results, highlighting a slight revenue increase but also acknowledging substantial doubt about its ability to continue as a going concern.

Biofrontera Inc. saw a revenue increase in the second quarter of 2024, but also reported a net loss, highlighting ongoing financial challenges.

Biofrontera Inc. reported a net loss of $10.4 million for Q1 2024 and faces going concern uncertainty, despite securing $7.3 million in financing and reducing inventory costs.